APSR2026-712

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-066
P85
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221095-46904-APSR 2026 poster 2026OCT26_434118.pdf
Format: PDF Only
08. Lung Cancer
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hiroshi Nakaoka * Chikamori Hospital Dept of Respiratory medicine Kochi Japan
Rina Matsuda - Chikamori Hospital Dept of Respiratory medicine Kochi Japan
Naoki Murata - Chikamori Hospital Dept of Respiratory medicine Kochi Japan
Eri Fujiwara - Chikamori Hospital Dept of Respiratory medicine Kochi Japan
Masayuki Ishida - Chikamori Hospital Dept of Infectious diseases Kochi Japan
Yoshihiro Ohkawa - Chikamori Hospital Dept of Gastroenterology Kochi Japan
Hirofumi Satake - Chikamori Hospital Dept of Urology Kochi Japan
Junko Nakashima - Chikamori Hospital Dept of Pathology Kochi Japan
 
 
 
 
 
 
 
Presenting Author Details
Hiroshi
Nakaoka
hnakaoka0206@gmail.com
+819094041942
41-50
Japan
Case Report
Unusual immune-related adverse events involving biliary tract, stomach, and bladder during lung cancer immunotherapy: a case series
Maximum 25 words
Abstract Content
 
 
 
 
Immune-related adverse events (irAEs) are well recognized complications of treatment with immune checkpoint inhibitors (ICIs); however, involvement of organs such as the biliary tract, stomach, and bladder is rare and not fully characterized. We report a case series of such unusual irAEs during lung cancer immunotherapy.
We retrospectively analyzed three patients with lung cancer who developed irAEs during ICI therapy. Case 1: A 51-year-old male with stage IV adenocarcinoma was treated with chemotherapy and ICIs. Seven months after initiation, he developed epigastric pain with cholestatic liver dysfunction. Imaging revealed irregular bile duct dilatation without obstruction. Case 2: A 62-year-old male with stage IV adenocarcinoma received chemotherapy and ICIs. Twelve months later, he developed heartburn and vomiting, and gastroscopy revealed diffuse mucosal inflammation. The diagnosis of irAE was confirmed by pathological evaluation. Case 3: A 56-year-old male with stage IV squamous cell carcinoma developed dysuria and nocturia two months after initiation of chemotherapy and ICIs. Immune-related cystitis was diagnosed based on cystoscopic biopsy findings. All patients were treated with corticosteroids; however, Case 1 required additional treatment with mycophenolate mofetil and Case 3 required infliximab.
These cases highlight that irAEs can involve uncommon organs, making diagnosis challenging. These events occurred across different ICIs, including anti-PD-1, anti-PD-L1, and combination therapy. Differentiation from infection, malignancy progression, or drug-induced toxicity is essential. Early recognition and prompt initiation of appropriate therapy may lead to favorable outcomes. Some cases required additional immunosuppressive therapy beyond corticosteroids. Corticosteroids alone may be inadequate, and evidence regarding optimal management of rare irAEs remains limited. Clinicians should be aware of these rare manifestations.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
immune-related adverse events, lung cancer, uncommon organs
maximum 3 keywords and no abbreviations, separated by commas
 
261